PDCD1 and esophageal squamous cell carcinoma: With increasing clinical use of PD‐1/PD‐L1 inhibitor combination therapies for second‐line ESCC treatment, there is a strong need for a systematic analysis to provide more robust evidence supporting this combination strategy in clinical practice.